ClinicalTrials.gg
CompletedNCT00535730Updated Apr 12, 2017Results posted

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

A Phase 3 interventional study of Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ and Comparator: placebo (concomitant-vaccine matched) in Herpes Zoster and Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
473
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Herpes Zoster by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Herpes Zoster · Merck & Co., Inc.

Enrollment
10th of 25
473 · median 354
Started
2007
with 5 others
Phase 3
14 of 27
none open now
Registered
5th of 27
by date

Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 14 in phase 3, and was the 5th registered.

Herpes Zoster

299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.

Browse Herpes Zoster studies →

Open to participants now

None of the 27 studies in Herpes Zoster by Merck & Co., Inc is open now. The open studies under Herpes Zoster, anywhere →

Who these studies take

Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Herpes Zoster by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are given alone, in adults 60 years of age and older.

03

Conditions studied

  • Herpes Zoster
  • Pneumococcal Infection
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 60 years of age or older
  • Stable underlying conditions
  • if female
  • Afebrile

Exclusion criteria

Exclusion Criteria:

  • Previously vaccinated with either vaccine
  • Immune deficiency
  • History of allergy to components in either vaccine
  • Concomitant antiviral therapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
473 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo Comparator

    Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ · Biological: Comparator: placebo (concomitant-vaccine matched)

  • Experimental
    2

    vaccine

    Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ · Biological: Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

Interventions

  • 0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period

    Also known as: ZOSTAVAX™

  • BiologicalComparator: placebo (concomitant-vaccine matched)

    Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.

  • BiologicalPneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23

    Drug page: 23-valent pneumococcal capsular polysaccharide vaccine

    Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.

    Also known as: PNEUMOVAX™ 23

06

What researchers measure

Primary outcomes

  1. Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination

    GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly. \*gpELISA = glycoprotein enzyme-linked immunosorbent assay

    Time frame: 4 weeks postvaccination

  2. Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.

    GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23. gpELISA = glycoprotein enzyme-linked immunosorbent assay.

    Time frame: Four weeks postvaccination

  3. Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.

    GMT of the PnPs serotype 3 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

    Time frame: Four weeks postvaccination

  4. Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.

    GMT of the PnPs serotype 14 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

    Time frame: Four weeks postvaccination

  5. Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.

    GMT of the PnPs serotype 19A antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

    Time frame: Four weeks postvaccination

  6. Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.

    GMT of the PnPs serotype 22F antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

    Time frame: Four weeks postvaccination

Secondary outcomes

  1. Safety and Tolerability of Both Vaccines When Administered Concomitantly.

    All adverse events were analyzed including serious adverse events; injection-site adverse events; Vaccination Report Card prompted systemic adverse events, including varicella-like rashes or herpes zoster-like rashes; all other systemic adverse events.

    Time frame: Eight weeks postvaccination

07

Results

Posted May 13, 2009

Participant flow

Phase III First subject enrolled on 18-Jun-2007. Last subject enrolled on 05-Dec-2007. The last subject's last visit was 11-Feb-2008. The study was conducted at 18 study centers throughout Canada, Australia, and Europe.

Participant flow — Overall Study
MilestoneNonconcomitant GroupConcomitant Group
Started236237
Completed234230
Not completed27
Withdrew: Adverse event11
Withdrew: Lost to follow-up01
Withdrew: Physician decision01
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject04

Outcome measures

PrimaryGeometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination

GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly. \*gpELISA = glycoprotein enzyme-linked immunosorbent assay

Time frame:
4 weeks postvaccination
Reported as:
Geometric mean · gpELISA units*/mL
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination
gpELISA units*/mLNonconcomitant GroupConcomitant Group
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination448.5 (400.3 to 502.4)371.6 (328.7 to 420.0)
Statistical analysis
  • Nonconcomitant Group vs Concomitant Group · longitudinal regression model · p = 0.244 (The threshold for statistical significance is 0.025. There is no adjustment for multiple comparisons.)Week 4 postvac, estimated responses, GMT ratio, 95% CI, p-value based on a longitudinal regression model adjusting for prevac titers and age (years)
SecondarySafety and Tolerability of Both Vaccines When Administered Concomitantly.

All adverse events were analyzed including serious adverse events; injection-site adverse events; Vaccination Report Card prompted systemic adverse events, including varicella-like rashes or herpes zoster-like rashes; all other systemic adverse events.

Time frame:
Eight weeks postvaccination
Reported as:
Number · Participants
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
ParticipantsNonconcomitant GroupConcomitant Group
Injection site AEs141136
Systemic AEs7470
Serious AEs42
Varicella-like Rash32
Zoster-like Rash11
PrimaryGeometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.

GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23. gpELISA = glycoprotein enzyme-linked immunosorbent assay.

Time frame:
Four weeks postvaccination
Reported as:
Geometric mean · gpELISA units/mL
Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.
gpELISA units/mLConcomitant Group
Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.1.9 (1.7 to 2.1)
Statistical analysis
  • Concomitant Group · t-test, 1 sided · p = <0.001 (The threshold for statistical significance is 0.025. There is no adjustment for multiple comparisons.)The one-sided p-value for testing acceptability for GMFR is computed based on t-test. CI is computed based on the t distribution
PrimaryGeometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.

GMT of the PnPs serotype 3 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Time frame:
Four weeks postvaccination
Reported as:
Geometric mean · micrograms/mL
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.
micrograms/mLNonconcomitant GroupConcomitant Group
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.1.2 (1.1 to 1.4)1.1 (1.0 to 1.2)
Statistical analysis
  • Nonconcomitant Group vs Concomitant Group · longitudinal regression model · p = <0.001 (The threshold for statistical significance is 0.025. There is no adjustment for multiple comparisons.)Week 4 postvac, estimated responses, GMT ratio, 95% CI, p-value based on a longitudinal regression model adjusting for prevac titers and age (years)
PrimaryGeometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.

GMT of the PnPs serotype 14 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Time frame:
Four weeks postvaccination
Reported as:
Geometric mean · micrograms/mL
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.
micrograms/mLNonconcomitant GroupConcomitant Group
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.26.5 (22.9 to 30.8)25.7 (21.8 to 30.3)
Statistical analysis
  • Nonconcomitant Group vs Concomitant Group · longitudinal regression model · p = <0.001 (The threshold for statistical significance is 0.025. There is no adjustment for multiple comparisons.)Week 4 postvac, estimated responses, GMT ratio, 95% CI, p-value based on a longitudinal regression model adjusting for prevac titers and age (years)
PrimaryGeometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.

GMT of the PnPs serotype 19A antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Time frame:
Four weeks postvaccination
Reported as:
Geometric mean · micrograms/mL
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.
micrograms/mLNonconcomitant GroupConcomitant Group
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.10.5 (8.7 to 12.6)10.5 (8.7 to 12.7)
Statistical analysis
  • Nonconcomitant Group vs Concomitant Group · longitudinal regression model · p = <0.001 (The threshold for statistical significance is 0.025. There is no adjustment for multiple comparisons.)Week 4 postvac, estimated responses, GMT ratio, 95% CI, p-value based on a longitudinal regression model adjusting for prevac titers and age (years)
PrimaryGeometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.

GMT of the PnPs serotype 22F antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Time frame:
Four weeks postvaccination
Reported as:
Geometric mean · micrograms/mL
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.
micrograms/mLNonconcomitant GroupConcomitant Group
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.2.8 (2.3 to 3.3)2.5 (2.1 to 3.0)
Statistical analysis
  • Nonconcomitant Group vs Concomitant Group · longitudinal regression model · p = <0.001 (The threshold for statistical significance is 0.025. There is no adjustment for multiple comparisons.)Week 4 postvac, estimated responses, GMT ratio, 95% CI, p-value based on a longitudinal regression model adjusting for prevac titers and age (years)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nonconcomitant Group———
Concomitant Group———
Most frequent serious events
Most frequent serious events
EventNonconcomitant GroupConcomitant Group
Dermatitis contactSkin and subcutaneous tissue disorders0/2361/235
VertigoEar and labyrinth disorders0/2361/235
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/2360/235
Non-Hodgkin's LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2360/235
HaematomaVascular disorders1/2360/235
DiverticulitisInfections and infestations1/2360/235
Global amnesiaNervous system disorders1/2360/235
Most frequent other events
Showing 10 of 32
Most frequent other events
EventNonconcomitant GroupConcomitant Group
Pain (PNEUMOVAX™ 23 injection site)General disorders82/23695/235
Pain (ZOSTAVAX™ injection site)General disorders68/23674/235
Erythema (ZOSTAVAX™ injection site)General disorders70/23672/235
Swelling (ZOSTAVAX™ injection site)General disorders63/23667/235
Swelling (PNEUMOVAX™ 23 injection site)General disorders30/23649/235
Erythema (PNEUMOVAX™ 23 injection site)General disorders30/23646/235
Pain (Placebo injection site)General disorders21/2368/235
HeadacheNervous system disorders4/23613/235
Pruritus (ZOSTAVAX™ injection site)General disorders8/23611/235
NasopharyngitisInfections and infestations5/2369/235

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nonconcomitant GroupConcomitant GroupTotal
Mean66.0 ± 5.666.3 ± 5.666.2 ± 5.6
Sex: Female, Male
Sex: Female, Male(Participants)Nonconcomitant GroupConcomitant GroupTotal
Female135138273
Male10197198
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Nonconcomitant GroupConcomitant GroupTotal
Asian112
Black or African American011
White235233468
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • MacIntyre CR, Egerton T, McCaughey M, Parrino J, Campbell BV, Su SC, Pagnoni MF, Stek JE, Xu J, Annunziato PW, Chan IS, Silber JL. Concomitant administration of zoster and pneumococcal vaccines in adults >/=60 years old. Hum Vaccin. 2010 Nov;6(11):894-902. doi: 10.4161/hv.6.11.12852. Epub 2010 Nov 1. PubMed 20980796 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in May 2009, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2007
First posted
Sep 26, 2007
Start
Jun 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
May 13, 2009
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00535730
Responsible party
Sponsor
First posted
Sep 26, 2007
Start date
Jun 2007
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
May 13, 2009
Last update
Apr 12, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion